CXC chemokines influence immune surveillance in immunological disorders: Polycystic ovary syndrome and endometriosis

Reproductive health is a worldwide challenge, but it is of particular significance to women during their reproductive age. Several female reproductive problems, including polycystic ovary syndrome (PCOS) and endometriosis, affect about 10 % of women and have a negative impact on their health, fertility, and quality of life. Small, chemotactic, and secreted cytokines are CXC chemokines. Both PCOS and endometriosis demonstrate dysregulation of CXC chemokines, which are critical to the development and progression of both diseases. Recent research has shown that both in humans and animals, CXC chemokines tend to cause inflammation. It has also been found that CXC chemokines are necessary for promoting angiogenesis and inflammatory responses. CXC chemokine overexpression is frequently associated with poor survival and prognosis. CXC chemokine levels in PCOS and endometriosis patients impact their circumstances significantly. Hence, CXC chemokines have significant potential as diagnostic and prognostic biomarkers and therapeutic targets. The molecular mechanisms through which CXC chemokines promote inflammation and the development of PCOS and endometriosis are currently unknown. This article will discuss the functions of CXC chemokines in the promotion, development, and therapy of PCOS and endometriosis, as well as future research directions. The current state and future prospects of CXC chemokine-based therapeutic strategies in the management of PCOS and endometriosis are also highlighted.

Automated summary

Reproductive health is particularly important for women during their reproductive age. Female reproductive problems such as polycystic ovary syndrome (PCOS) and endometriosis affect about 10% of women, negatively impacting their health, fertility, and quality of life. CXC chemokines, small chemotactic and secreted cytokines, are found to be dysregulated in both PCOS and endometriosis, playing a critical role in the development and progression of these diseases. Studies have shown that CXC chemokines promote inflammation and are involved in angiogenesis and inflammatory responses. Overexpression of CXC chemokines is associated with poor survival and prognosis. The levels of CXC chemokines significantly impact the circumstances of PCOS and endometriosis patients, indicating their potential as diagnostic and prognostic biomarkers and therapeutic targets. The molecular mechanisms underlying how CXC chemokines promote inflammation and the development of PCOS and endometriosis are currently unknown. This article aims to discuss the functions of CXC chemokines in the promotion, development, and therapy of PCOS and endometriosis, as well as future research directions. The current state and future prospects of CXC chemokine-based therapeutic strategies in managing PCOS and endometriosis are also highlighted.